Gene therapy for Parkinson's disease

Area of Science:

• Neuroscience
• Genetics
• Cell Biology

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons.
• Current treatments for PD primarily manage symptoms and do not halt disease progression.
• Gene therapy offers a potential strategy to address the underlying pathology of PD.

Purpose of the Study:

• To review and present advancements in gene therapy for experimental Parkinson's disease models.
• To evaluate the efficacy of ex vivo and in vivo gene therapy approaches for PD.
• To investigate the potential of targeting the caspase cascade for neuroprotection in PD.

Main Methods:

• Development of a modified pseudo-typed retrovirus production system for efficient gene transfer into neuronal progenitor cells (NPCs).
• Utilizing adeno-associated virus (AAV) vectors for in vivo gene delivery to neurons, minimizing inflammatory responses.
• Establishing in vivo models of PD, including MPTP-induced neurodegeneration, to test gene therapy interventions.

Main Results:

• High-titer retroviral vectors were successfully produced for efficient gene introduction into NPCs.
• AAV-mediated delivery of apoptotic protease activating factor-1-dominant negative inhibitor (Apaf-1-DN) prevented nigrostriatal degeneration in MPTP-treated mice.
• The study demonstrated the feasibility of targeting the caspase cascade via gene therapy for neuroprotection in PD models.

Conclusions:

• Neuronal progenitor cells (NPCs) are a suitable target for ex vivo gene therapy in PD.
• Adeno-associated virus (AAV) vectors are effective for in vivo gene therapy in neuronal targets.
• Inhibition of the caspase cascade through gene therapy, specifically Apaf-1-DN delivery, shows potential as an anti-mitochondrial apoptotic strategy for PD treatment.